

# FORBIUS

## **AVID100 Featured in an Invited Oral Presentation at the 9<sup>th</sup> Annual World ADC Summit**

- Forbius will be providing an update on development of AVID100, an anti-EGFR ADC
- Phase 1 established a high RP2D that is predicted to be therapeutically active; Phase 2a trials underway
- AVID100 is the only broadly active anti-EGFR ADC in clinical development

(November 6, 2018) – Forbius, a clinical stage company developing biotherapeutics targeting EGFR and TGF- $\beta$  pathways, announced today an invited oral presentation of AVID100 at the [9<sup>th</sup> Annual World ADC Meeting](#). Robert Lutz, Chief Development Officer of Forbius, will give a presentation entitled "Preclinical & Clinical Development of AVID100: An EGFR-Targeting Antibody Drug Conjugate" on November 13, 2018 at 11 AM Pacific Time.

The AVID100 Phase 1 study was completed mid 2018, having enrolled 24 patients, and established a recommended Phase 2 dose (RP2D) of AVID100 of 240 mg/m<sup>2</sup> (~6 mg/kg). This is one of the highest RP2Ds reported for maytansinoid payload ADCs ([Deslandes, MAbs. 2014 Jul 1; 6\(4\):859-870](#)) and is expected to be in the therapeutically active range based on preclinical efficacy studies. The majority of treatment related adverse events at RP2D were well-tolerated and grade 1 and 2 in severity. Of note, skin-related side-effects, that have been observed previously for therapeutic anti-EGFR antibodies, remained low grade and well tolerated.

AVID100 is currently undergoing Phase 2a clinical trials in EGFR overexpressing tumors to further evaluate safety and efficacy.

### **About AVID100**

AVID100 is a highly potent EGFR-targeting antibody-drug conjugate (ADC) that was engineered to achieve enhanced anti-tumor efficacy without a corresponding increase in toxicity against skin and other EGFR-expressing normal tissues. In preclinical studies, AVID100 demonstrated significant anti-cancer activity, including in EGFR overexpressing tumor models that are resistant to marketed EGFR inhibitors. AVID100 is the only broadly active anti-EGFR ADC in clinical development.

# FORBIUS

## **About Forbius: Targeting TGF-beta and EGFR Pathways in Fibrosis and Cancer**

Forbius is a clinical stage protein engineering company that designs, develops, and commercializes biotherapeutics for the treatment of fibrosis and cancer. Our current focus is the development of agents targeting the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways.

Our lead program targeting the TGF-beta pathway is AVID200. AVID200 is a rationally designed and highly potent TGF-beta 1 & 3 inhibitor. This TGF-beta isoform selectivity was chosen in order to achieve an optimal therapeutic index. The AVID200 program has been cleared by the FDA for two Phase 1b clinical trials in fibrotic indications, as well as a Phase 1 clinical trial in solid tumors. Additional clinical trials in fibrotic indications are planned for 2019.

Forbius' lead program targeting the EGFR pathway is AVID100. AVID100 is an anti-EGFR antibody-drug conjugate. This program has completed a Phase 1 clinical trial and has commenced Phase 2a clinical trials in EGFR overexpressing solid tumors. For more information, please visit [www.forbius.com](http://www.forbius.com).